These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24013728)

  • 1. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors.
    Maurer B; Distler A; Dees C; Khan K; Denton CP; Abraham D; Gay RE; Michel BA; Gay S; Hw Distler J; Distler O
    Ann Rheum Dis; 2013 Dec; 72(12):2039-46. PubMed ID: 24013728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
    Akhmetshina A; Venalis P; Dees C; Busch N; Zwerina J; Schett G; Distler O; Distler JH
    Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials.
    Iwamoto N; Distler JH; Distler O
    Curr Rheumatol Rep; 2011 Feb; 13(1):21-7. PubMed ID: 21042889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro.
    Hinchcliff M; Huang CC; Ishida W; Fang F; Lee J; Jafari N; Wilkes M; Bhattacharyya S; Leof E; Varga J
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S86-96. PubMed ID: 22691216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
    Beyer C; Distler JH; Distler O
    Swiss Med Wkly; 2010; 140():w13050. PubMed ID: 20419513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.
    Pannu J; Asano Y; Nakerakanti S; Smith E; Jablonska S; Blaszczyk M; ten Dijke P; Trojanowska M
    Arthritis Rheum; 2008 Aug; 58(8):2528-37. PubMed ID: 18668566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis.
    Distler JH; Distler O
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v10-1. PubMed ID: 18784126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis.
    Maurer B; Reich N; Juengel A; Kriegsmann J; Gay RE; Schett G; Michel BA; Gay S; Distler JH; Distler O
    Ann Rheum Dis; 2012 Aug; 71(8):1382-7. PubMed ID: 22523431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular framework for response to imatinib mesylate in systemic sclerosis.
    Chung L; Fiorentino DF; Benbarak MJ; Adler AS; Mariano MM; Paniagua RT; Milano A; Connolly MK; Ratiner BD; Wiskocil RL; Whitfield ML; Chang HY; Robinson WH
    Arthritis Rheum; 2009 Feb; 60(2):584-91. PubMed ID: 19180499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
    Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
    Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EphB2 Receptor Promotes Dermal Fibrosis in Systemic Sclerosis.
    Egal ESA; Kamdem SD; Yoshigi M; Yang CC; Pellizzari S; Kameni EM; Helms MN; Assassi S; Henkemeyer M; Frech TM; Mimche PN
    Arthritis Rheumatol; 2024 Aug; 76(8):1303-1316. PubMed ID: 38589317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice.
    Rhee CK; Lee SH; Yoon HK; Kim SC; Lee SY; Kwon SS; Kim YK; Kim KH; Kim TJ; Kim JW
    Respiration; 2011; 82(3):273-87. PubMed ID: 21659722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease.
    Zerr P; Distler A; Palumbo-Zerr K; Tomcik M; Vollath S; Dees C; Egberts F; Tinazzi I; Del Galdo F; Distler O; Schett G; Spriewald BM; Distler JH
    Am J Pathol; 2012 Nov; 181(5):1672-80. PubMed ID: 22940072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
    Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
    Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
    Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis.
    Akhmetshina A; Dees C; Pileckyte M; Maurer B; Axmann R; Jüngel A; Zwerina J; Gay S; Schett G; Distler O; Distler JH
    FASEB J; 2008 Jul; 22(7):2214-22. PubMed ID: 18326784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
    Distler JH; Distler O
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study.
    Soria A; Cario-André M; Lepreux S; Rezvani HR; Pasquet JM; Pain C; Schaeverbeke T; Mahon FX; Taïeb A
    Dermatology; 2008; 216(2):109-17. PubMed ID: 18216472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.